haemophilia

News

Pfizer ducks out of Sangamo haemophilia A alliance

Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.

News

Pfizer bags EU okay for haemophilia drug Hympavzi

Pfizer's Hympavzi has become the first once-weekly subcutaneous treatment for people living with severe haemophilia B in the EU

News

Novo Nordisk closes on EU okay for haemophilia antibody

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia.

News

Pfizer rounds out haemophilia portfolio with FDA approval

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia, becoming the pharma group’s second new therapy for the blood disorder this year.

News

Pfizer's haemophilia B gene therapy gets EU green light

There will soon be two gene therapies available for patients with haemophilia B in the EU after the European Commission approved Pfizer's fidanacogene elaparvovec under the Durveqtix brand

News